|
Continuation of d10: 4968-60 lead, implanted: (b)(6) 2009; 3058 ipg, implanted: (b)(6) 2022; 978b128 lead, implanted: (b)(6) 2022; dtma1d1 crt-d, implanted: (b)(6) 2022.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported that the right atrial (ra) lead exhibited undersensing on a stored atrial tachycardia/atrial fibrillation (at/af) episode, resulting in termination of the at/af detected event in progress.It was also reported that the left ventricular (lv) lead had recently exhibited an increase in pacing impedance and varying pacing impedance.The lv lead pacing impedance was high and out-of-range.The lv lead also exhibited a recent increase in thresholds, with a possible loss of capture.The lv lead thresholds were high.The leads remain in use.No patient complications have been reported as a result of this event.
|